Recent News

• 06.02.2025 - Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
• 06.02.2025 - Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
• 05.08.2025 - Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
• 05.08.2025 - Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
• 04.23.2025 - Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
• 04.23.2025 - Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
• 04.15.2025 - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.15.2025 - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.15.2025 - Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
• 04.15.2025 - Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Recent Filings

• 05.13.2025 - EFFECT Notice of Effectiveness
• 05.08.2025 - 8-K Current report
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - S-3/A Registration statement under Securities Act of 1933
• 05.08.2025 - EX-99.1 EX-99.1
• 04.30.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEF 14A Other definitive proxy statements
• 04.23.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors